Abstract:ObjectiveTo investigate the clinical effect of Ribavirin Aerosol on the treatment of children with handfoot-mouth disease and the negative conversion of the virus.MethodsAltogether 74 cases of children with hand-footmouth disease who were treated in our hospital from March 2016 to June 2016 were selected and randomly divided into control group and treatment group,with 37 cases in each group.Both groups were given basic treatment and treatment group was treated with Ribavirin Aerosol in addition.The total effective rate,clinical symptom improvement time,the virus negative conversion rate and adverse reaction rate of two groups were observed and compared after 1 week of treatment.ResultsAfter 1 week of treatment,the total effective rate of treatment group (97.30%)was higher than that in the control group(78.37%),the adverse reaction rate of treatment group(2.70%)was lower than that in the control group(13.51%),the differences were statistically significant(P<0.05).The herpes crusting,disappearance and initial eating time of treatment group were shorter than those in the control group,the differences were statistically significant(P<0.05).The positive rate of virus of two groups by using throat swab before treatment were compared,the differences were not statistically significant(P>0.05).After 1 week of treatment,the virus negative conversion rate of the patients in the treatment group was higher than that in the control group,the difference was statistically significant(P<0.05).ConclusionRibavirin Aerosol demonstrates its significant clinical effect,safety and reliability in treatment of children with hand-footmouth disease.
孙玲玲;蔡德丰;陈运生. 利巴韦林气雾剂治疗儿童手足口病的效果评价[J]. 中国当代医药, 2017, 24(23): 85-87.
SUN Ling-ling;CAI De-feng;CHEN Yun-sheng. Effectiveness evaluation of Ribavirin Aerosol on the treatment of children with hand-foot-mouth disease. 中国当代医药, 2017, 24(23): 85-87.
Lack G,Caufield H,Penagos M.The link between otitis meia with effusion and allergy:apotential role for intranasal corticosteroids[J].Pediatr Allergy Immunol,2011,22(3):258-266.
Tacon CL,McCdfrey J,Delaney A.Dobutamine for patients with severe heart failure:a systematic review and meta-analysis of randomised controlled trials[J].Intensive Care Med,2012,38(3):359-367.